These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 24955866)

  • 41. Role of 5-HT1A Receptor in Vilazodone-Mediated Suppression of L-DOPA-Induced Dyskinesia and Increased Responsiveness to Cortical Input in Striatal Medium Spiny Neurons in an Animal Model of Parkinson's Disease.
    Altwal F; Padovan-Neto FE; Ritger A; Steiner H; West AR
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641332
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Fidalgo C; Ko WK; Tronci E; Li Q; Stancampiano R; Chuan Q; Bezard E; Carta M
    Neuroscience; 2015 Jul; 298():389-96. PubMed ID: 25907446
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.
    Kumar R; Riddle LR; Griffin SA; Chu W; Vangveravong S; Neisewander J; Mach RH; Luedtke RR
    Neuropharmacology; 2009; 56(6-7):956-69. PubMed ID: 19371586
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β.
    Muñoz A; Garrido-Gil P; Dominguez-Meijide A; Labandeira-Garcia JL
    Exp Neurol; 2014 Nov; 261():720-32. PubMed ID: 25160895
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synergistic effect of serotonin 1A and serotonin 1B/D receptor agonists in the treatment of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
    Thomsen M; Stoica A; Christensen KV; Fryland T; Mikkelsen JD; Hansen JB
    Exp Neurol; 2022 Dec; 358():114209. PubMed ID: 35988699
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of the Serotonin 5-HT
    Newman-Tancredi A; Varney MA; McCreary AC
    Neurochem Res; 2018 May; 43(5):1035-1046. PubMed ID: 29572645
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
    Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
    Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.
    Lindgren HS; Ohlin KE; Cenci MA
    Neuropsychopharmacology; 2009 Nov; 34(12):2477-88. PubMed ID: 19606087
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
    Mela F; Millan MJ; Brocco M; Morari M
    Neuropharmacology; 2010 Feb; 58(2):528-36. PubMed ID: 19733554
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
    Bezard E; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
    Mov Disord; 2013 Jul; 28(8):1088-96. PubMed ID: 23389842
    [TBL] [Abstract][Full Text] [Related]  

  • 54. L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.
    Huot P; Johnston TH; Koprich JB; Espinosa MC; Reyes MG; Fox SH; Brotchie JM
    Behav Pharmacol; 2015 Feb; 26(1-2):101-8. PubMed ID: 25303957
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
    Chagniel L; Robitaille C; Lebel M; Cyr M
    Neurobiol Dis; 2012 Jan; 45(1):645-55. PubMed ID: 22037042
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease.
    Lindenbach D; Dupre KB; Eskow Jaunarajs KL; Ostock CY; Goldenberg AA; Bishop C
    Brain Res; 2013 Nov; 1537():327-39. PubMed ID: 24060645
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Spinnewyn B; Mautino G; Marin JG; Rocher MN; Grandoulier AS; Ferrandis E; Auguet M; Chabrier PE
    Neuropharmacology; 2011 Mar; 60(4):692-700. PubMed ID: 21129389
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
    Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C
    Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease.
    Lipari N; Centner A; Glinski J; Cohen S; Manfredsson FP; Bishop C
    Neurobiol Dis; 2023 Jan; 176():105965. PubMed ID: 36526089
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat.
    Bhide N; Lindenbach D; Surrena MA; Goldenberg AA; Bishop C; Berger SP; Paquette MA
    Psychopharmacology (Berl); 2013 Jun; 227(3):533-44. PubMed ID: 23389756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.